Axerion Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axerion Therapeutics Inc.
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.
FitLife direct-to-consumer, online sales fuel quarter; AXIM Wellness launching CBD gum; Canadian firm acquiring PA cannabis cultivator; Clorox' lifestyle division flat in latest quarter despite strong sales of NutraNext supplements; and New Age delays rolling beverage line on confusing FDA regulation messaging.
After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.
“We love that we’re in differentiated segments here, emerging segments, not single letter vitamins, but product benefits that are scientifically grounded and that start to have a really strong following among consumers,” Clorox CEO Bennor Dorer says of the firm's recent Nutranext acquisition. He explained the “rationale” for buying a business that competes in a “fragmented category” without a brand leader during Clorox' third-quarter earnings briefing.